Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSarc
2024-513469-38-00Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in soft tissue sarcoma (STS), Malignant Fibrous Histiocytoma (MFH) and Liposarcoma comparing Pembrolizumab with Pembrolizumab + olaparib (2 arms). Primary endpoint: Increase in CD8+ T-cell tumor infiltration density. Started Dec 2024; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
soft tissue sarcoma (STS)Malignant Fibrous Histiocytoma (MFH)Liposarcoma
Beyond the preview
Go deeper on 2024-513469-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513469-38-00.